In last Q2 with Humira market lock, AbbVie leans on best-seller to offset Imbruvica losses

The North Chicago, Illinois pharma achieved second-quarter revenues of $14.6 billion, a 6.1% operational increase in the second quarter, thanks to Humira. The med scored a 9% U.S. revenue increase to $4.66 billion. International revenues decreased by 7.3% to $699 million, which the company chalked up to biosimilar competition.